Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/13/2025

Clip Placement Indication in Breast Cancer

Primary Tumor Clip Placement

  • The National Comprehensive Cancer Network recommends clip placement in the breast tumor for all patients anticipated to receive neoadjuvant/preoperative systemic therapy, regardless of tumor stage, to demarcate the tumor bed for post-chemotherapy surgical management 1, 2, 3
  • Core biopsy with placement of image-detectable marker(s) must be performed at diagnosis in any patient planned for neoadjuvant therapy to mark the original tumor location before treatment-induced shrinkage or complete response 1, 3
  • Clip placement should occur at the time of diagnostic or research biopsy, ideally before starting any systemic therapy 2
  • If a clip was not placed initially and the tumor shows significant response after the first cycle(s) of chemotherapy suggesting possible complete response, it is imperative to place a clip immediately—even if mastectomy is planned—as it may become impossible to identify the correct surgical area after treatment completion 2

Rationale for Tumor Clip Placement

  • Complete or near-complete clinical responses are common with neoadjuvant therapy, making the original tumor location difficult or impossible to identify at surgery without marking 1, 4, 5
  • The clips aid in post-chemotherapy resection of the original tumor area, ensuring adequate surgical margins and appropriate radiation field planning 1, 4
  • Neoadjuvant therapy increases breast conservation rates, but accurate localization of the pre-treatment tumor bed is essential for oncologic safety 1, 5

Axillary Lymph Node Clip Placement

  • Clinically positive axillary lymph nodes (cN+) that are sampled by FNA or core biopsy must be clipped with an image-detectable marker at the time of biopsy 1, 3, 6
  • Clinically negative axillary lymph nodes that appear suspicious on ultrasound should be sampled by FNA or core biopsy and clipped if positive 1, 3, 6
  • The clipped positive lymph nodes must be removed at definitive surgery if the biopsy was positive before neoadjuvant therapy 1, 3, 6

Stage-Specific Considerations

  • Clip placement is indicated for patients with clinical stage I, IIA, or IIB disease (T1-T3, N0-N1) who desire breast preservation and will receive neoadjuvant therapy 1, 3
  • Even for small tumors (T1), if neoadjuvant therapy is planned, clips should be placed as complete responses can occur regardless of initial tumor size 2
  • For inoperable, non-inflammatory locally advanced disease (clinical stages IIIA [except T3N1M0], IIIB, or IIIC), clip placement is essential as neoadjuvant therapy is standard and may produce dramatic responses 1
  • These patients have higher likelihood of complete or near-complete responses, making clip placement critical for surgical planning 1

Common Pitfalls and How to Avoid Them

  • Pitfall: Delaying clip placement until after starting chemotherapy, place clips at initial diagnostic biopsy 2
  • Pitfall: Assuming mastectomy patients don't need clips, even with planned mastectomy, clips are imperative for identifying the tumor bed for pathologic assessment and potential radiation planning 2
  • Pitfall: Removing too much tumor tissue during biopsy, obtain adequate but not excessive tissue, and place the clip in the remaining tumor 2
  • Pitfall: Failure to document clip placement, communication between radiology, surgery, and pathology is essential to ensure clips are identified and the marked areas are appropriately excised 2, 7

Axillary Clips in Breast Cancer Management

Primary Indication and Accuracy

  • Clip placement into the biopsied node may improve the accuracy of post-neoadjuvant sentinel lymph node biopsy, as recommended by the American College of Radiology 8
  • Without clips, identifying which node was originally positive becomes impossible after chemotherapy-induced response, highlighting the importance of clip placement in patients planned for neoadjuvant therapy with documented nodal involvement 9

Surgical Management After Neoadjuvant Therapy

  • If the axilla is initially clinically positive but has clinical complete response after treatment, sentinel lymph node biopsy may be performed only if the clipped node is removed, dual tracer is used, and more than 2 sentinel nodes are removed, according to the Journal of the American College of Radiology 9
  • The false-negative rate of sentinel lymph node biopsy after neoadjuvant chemotherapy ranges from 7.3% to 12.6%, which improves with dual tracer method and removal of ≥3 sentinel nodes, as reported by the Journal of the American College of Radiology 9

Accuracy of Post-Neoadjuvant Axillary Assessment

  • Imaging cannot reliably detect residual nodal disease after neoadjuvant chemotherapy, with ultrasound, MRI, and PET/CT having reported sensitivities of only 69.8%, 61.0%, and 63.2% respectively for detecting residual disease, as stated by the Journal of the American College of Radiology 10
  • Surgical intervention, either sentinel node biopsy or axillary dissection, is necessary after completion of neoadjuvant treatment, due to the limitations of imaging modalities in detecting residual disease 10

Critical Pitfalls to Avoid

  • Performing pre-neoadjuvant sentinel lymph node biopsy is not recommended because assessment of nodal response in the axilla becomes unreliable after excision of a positive node, and it invalidates the residual cancer burden score and ypN stage, as advised by the Annals of Oncology 8
  • Assuming imaging can replace surgical staging is a pitfall, as even with complete clinical response on imaging, the false-negative rate of imaging modalities is too high to omit surgical assessment, according to the Journal of the American College of Radiology 9 and 10